Rimactane450 mg

Established / Guideline-Supported Uses

• Tuberculosis (TB): Rimactane is a cornerstone, first-line antitubercular agent. It is always used as part of a multi-drug combination regimen (typically with isoniazid, pyrazinamide, and ethambutol in the initial intensive phase, followed by Rimactane plus isoniazid in the continuation phase). Rimactane is never used as monotherapy for active TB because resistance develops rapidly.
• Prophylaxis of meningococcal carriers: Rimactane is used to eliminate Neisseria meningitidis from the nasopharynx of asymptomatic carriers to prevent spread, in close contacts of a case of meningococcal disease. It is not used to treat active meningococcal disease itself.
• Prophylaxis against Haemophilus influenzae type b (Hib): given to close contacts (including children) to reduce the risk of invasive Hib disease, per public health guidance.

Adjunct / Combination-Only Uses

• Leprosy (Hansen's disease): Rimactane is a key component of WHO multidrug therapy (MDT) regimens, always combined with dapsone (and clofazimine for multibacillary disease). It is not used alone for leprosy.
• Serious staphylococcal infections (e.g., prosthetic device or bone/joint infections): occasionally added as an adjunct to another active antistaphylococcal antibiotic to improve biofilm penetration; not used as a single agent because resistance emerges quickly.
• Brucellosis: used in combination with doxycycline (or other agents) per treatment guidelines.

Off-Label Use

• Legionella pneumonia (severe cases, as an adjunct to a macrolide or fluoroquinolone) and select other atypical or resistant bacterial infections may use Rimactane off-label in combination therapy, based on specialist assessment.

Rimactane should only be prescribed by, or under the direct guidance of, a physician experienced in managing these infections.

Each dosage form contains Rifampicin as the active pharmaceutical ingredient. Common formulations include:

• Capsules/Tablets: Rifampicin 150 mg or 450 mg
• Oral suspension/syrup: Rifampicin 100 mg/5 mL
• Powder for injection (IV): Rifampicin for reconstitution, where available

Rifampicin is frequently combined with other antitubercular drugs (isoniazid, pyrazinamide, ethambutol) in fixed-dose combination products; this monograph describes Rifampicin as a single active ingredient.

Rimactane is a semisynthetic antibiotic derived from Amycolatopsis rifamycinica (formerly Streptomyces mediterranei), belonging to the rifamycin class of antimicrobials. It is bactericidal against actively dividing organisms and has a distinctive broad-spectrum activity against mycobacteria (including Mycobacterium tuberculosis and M. leprae) as well as several gram-positive and some gram-negative bacteria.

Rimactane is a critical component of multi-drug regimens for tuberculosis and leprosy, and is also used for short-course prophylaxis against meningococcal and Haemophilus influenzae type b carriage. Its most notable pharmacologic feature is potent induction of hepatic cytochrome P450 enzymes, which leads to numerous clinically important drug interactions, and it commonly causes harmless orange-red discoloration of body fluids.

Mechanism of Action

Rifampicin inhibits bacterial DNA-dependent RNA polymerase by binding to its beta subunit, blocking the initiation of RNA chain synthesis (transcription). Because human RNA polymerase is structurally different, Rifampicin is selectively toxic to bacteria and has minimal effect on human cells at therapeutic concentrations. This action is bactericidal against actively multiplying organisms, including intracellular and slowly dividing "persister" mycobacteria, which is why Rifampicin is essential for sterilizing tuberculosis lesions.

Pharmacokinetics

• Absorption: well absorbed orally; food reduces and delays absorption, so it is typically taken on an empty stomach.
• Distribution: widely distributed into body tissues and fluids, including cerebrospinal fluid (especially with inflamed meninges); crosses the placenta.
• Metabolism: hepatically metabolized (deacetylation); undergoes enterohepatic recirculation and is a potent inducer of cytochrome P450 enzymes (CYP3A4, CYP2C9, and others), which increases its own metabolism (autoinduction) over the first 1-2 weeks of therapy.
• Elimination: primarily excreted in bile and feces, with a smaller portion renally eliminated; elimination half-life is roughly 2-5 hours and shortens with continued dosing due to autoinduction.

Rimactane should be taken orally on an empty stomach, 1 hour before or 2 hours after a meal, with a full glass of water, to ensure optimal absorption. If severe gastrointestinal upset occurs, it may be taken with a small amount of food after consulting a physician. Capsules/tablets should be swallowed whole; the oral suspension should be shaken well before measuring the dose with an appropriate measuring device. An intravenous formulation, where available, is administered by slow infusion by trained healthcare personnel. Antacids, if needed, should be taken at least 1 hour after Rimactane to avoid reduced absorption.

Rimactane is a potent inducer of hepatic cytochrome P450 enzymes (particularly CYP3A4) and can significantly reduce the blood levels and efficacy of many co-administered drugs. Clinically significant interactions include:

• Hormonal contraceptives: Rimactane markedly reduces contraceptive efficacy; patients should be advised to use an alternative or additional non-hormonal method of contraception during and after treatment.
• Warfarin and other oral anticoagulants: Rimactane reduces anticoagulant effect; more frequent INR monitoring and dose adjustment are required.
• Antiretroviral drugs (protease inhibitors, some NNRTIs, integrase inhibitors): Rimactane can cause substantial loss of antiretroviral efficacy through enzyme induction; concurrent use with certain protease inhibitors (e.g., ritonavir-boosted saquinavir, atazanavir, darunavir, fosamprenavir, tipranavir) is contraindicated (see Contraindications). Any concurrent antiretroviral regimen must be reviewed by a specialist before starting Rimactane.
• Azole antifungals (e.g., ketoconazole, itraconazole, fluconazole): reduced antifungal levels; concurrent use may lead to treatment failure of the antifungal, and antifungals may also lower Rimactane levels.
• Anticonvulsants (e.g., phenytoin), corticosteroids, oral hypoglycemic agents (sulfonylureas), methadone, cyclosporine, and other immunosuppressants: reduced efficacy due to enzyme induction; dose adjustment of these drugs may be required.
• Antacids, opioids, and anticholinergics: may reduce absorption of Rimactane; separate dosing by at least 1 hour.

Because the interaction list is extensive, a physician or pharmacist should review all concurrent medications (prescription, over-the-counter, and herbal) whenever Rimactane is started or stopped.

Common

• Harmless orange-red discoloration of urine, tears, sweat, saliva, and sputum (patients should be counseled about this in advance; it can permanently stain soft contact lenses)
• Gastrointestinal upset: nausea, vomiting, abdominal discomfort, diarrhea, loss of appetite
• Headache, dizziness, drowsiness

Less Common but Clinically Important

• Hepatotoxicity: elevated liver enzymes, hepatitis, jaundice (see Precautions and Warnings)
• "Flu-like syndrome" (fever, chills, myalgia, headache) — more common with intermittent (less than daily) dosing schedules
• Hypersensitivity reactions: rash, pruritus, urticaria; rarely, severe cutaneous reactions
• Hematologic effects: thrombocytopenia, hemolytic anemia, leukopenia (rare)
• Renal effects: interstitial nephritis, acute kidney injury (rare, more common with intermittent high-dose regimens or with resumption after interruption)

Patients should seek prompt medical attention for yellowing of skin/eyes, unusual bleeding or bruising, severe rash, or persistent fever, as these may indicate a serious reaction.

Pregnancy

Rimactane crosses the placenta. Data are limited; Rimactane should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus — for example, active tuberculosis in pregnancy is generally treated because untreated TB poses a greater risk to mother and baby than treatment. When Rimactane is given close to delivery, it has been associated with postnatal hemorrhage in the mother and newborn; a physician may consider vitamin K supplementation for the mother and/or newborn in this situation. A physician should always be consulted before use in pregnancy.

Lactation

Rimactane passes into breast milk in small amounts. Because of theoretical concerns (tumorigenicity was observed in animal studies) and limited human data, breastfeeding mothers should consult their physician, who will weigh the benefits of breastfeeding and maternal treatment against the theoretical risk to the infant; many guidelines consider treatment compatible with continued breastfeeding when TB treatment is medically necessary, but this decision should be individualized with medical advice.

Hepatotoxicity (Most Important Warning)

Rimactane can cause liver dysfunction, and fatal hepatitis has occurred, particularly in patients with pre-existing liver disease, chronic alcohol use, or those taking other hepatotoxic drugs (including isoniazid, with which it is often combined). Baseline liver function tests (AST/ALT, bilirubin) should be obtained before starting therapy and monitored periodically (e.g., every 2-4 weeks) during treatment, especially in combination regimens. Rimactane should be discontinued or the regimen reassessed promptly if signs of hepatocellular damage (jaundice, marked enzyme elevation, persistent nausea/vomiting) occur.

Antitubercular Treatment Adherence

Complete the full prescribed course of treatment exactly as directed by your physician (often 6 months or longer for tuberculosis). Do not stop, extend, skip doses, or share this medicine with others without medical advice. Premature discontinuation or irregular dosing is a leading cause of treatment relapse and multidrug-resistant tuberculosis (MDR-TB), which is far more difficult and costly to treat.

Other Precautions

• Counsel patients in advance about harmless orange-red discoloration of urine, tears, sweat, and saliva; soft contact lenses may be permanently stained and should not be worn during treatment.
• Use with caution in patients with a history of porphyria, as Rimactane may exacerbate porphyria.
• Review all concurrent medications for significant drug interactions before starting Rimactane (see Interactions), especially hormonal contraceptives, anticoagulants, and antiretroviral drugs.
• Intermittent (non-daily) dosing schedules are associated with a higher risk of flu-like syndrome, thrombocytopenia, and renal reactions and are generally avoided unless specifically directed.
• Use only under medical supervision in patients with impaired hepatic function.

Symptoms of Rimactane overdose may include nausea, vomiting, abdominal pain, itching, headache, increasing lethargy, and a characteristic brownish-red or orange discoloration of the skin, urine, sweat, saliva, and tears (the degree of discoloration may indicate the amount ingested). Severe overdose may cause liver enlargement, jaundice, elevated liver enzymes, and cardiac arrhythmias, and can rapidly progress, especially in patients with pre-existing liver disease or in young children.

Rimactane overdose is a medical emergency. Seek immediate medical attention or contact your local emergency services/poison control center right away. Do not attempt to treat an overdose at home. Management is supportive and may include gastric decontamination (if presenting soon after ingestion, as advised by a physician), monitoring of liver function and vital signs, and in severe cases, hospital-based measures such as forced diuresis or dialysis performed by medical professionals.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Do not use after the expiry date.

Pediatric Patients

Rimactane is used in children for tuberculosis (10-20 mg/kg/day, maximum 600 mg/day) and for meningococcal/Hib prophylaxis with weight- and age-based dosing (see Dosage and Administration). Liver function should be monitored as in adults, particularly when combined with isoniazid.

Elderly Patients

No specific dose adjustment is generally required based on age alone, but elderly patients may have a higher baseline risk of hepatic impairment and should be monitored closely for hepatotoxicity and drug interactions, given the likelihood of concurrent medications.

Hepatic Impairment

Use with caution and only when clearly necessary; more frequent liver function monitoring is required (see Precautions and Warnings).

Renal Impairment

Dose adjustment is generally not required for standard TB dosing, as Rimactane is mainly eliminated via the liver/bile; caution is advised with high-dose or intermittent regimens in severe renal impairment.

For tuberculosis, Rimactane is typically continued for at least 6 months as part of a standard combination regimen (a 2-month intensive phase followed by at least a 4-month continuation phase), though duration may extend to 9-12 months or longer for certain forms (e.g., TB meningitis, bone/joint TB) based on physician assessment. For meningococcal or Hib carrier prophylaxis, treatment is short (2 days). For leprosy, WHO multidrug therapy with Rimactane typically continues for 6 to 12 months or longer depending on disease classification. The exact duration must always be determined and confirmed by the treating physician, and the full course must be completed even if symptoms improve earlier.

Where an injectable powder form of Rimactane is used, it must be reconstituted and further diluted strictly according to the manufacturer's instructions by a trained healthcare professional immediately before intravenous infusion; reconstituted/diluted solution should be used within the time window specified by the manufacturer and protected from light. This does not apply to oral capsule, tablet, or suspension formulations.

C

Rimactane is approved for use in children for the treatment of tuberculosis, dosed at 10-20 mg/kg once daily (maximum 600 mg/day) as part of a combination regimen, and for short-course prophylaxis against meningococcal disease and Haemophilus influenzae type b, using weight- and age-based dosing, including specific dosing for infants under 1 month of age (see Dosage and Administration table). Safety and efficacy for other, less-established uses (e.g., certain adjunctive off-label uses) have not been specifically established in children, and such use should only occur under specialist pediatric guidance. Liver function should be monitored during treatment, as in adults.